sábado, 21 de noviembre de 2026

Is MAHA’s think tank in the tank? Tax filings show low reserves Known for D.C. roundtables, MAHA Institute was down to $171,000 in December (++)

https://www.statnews.com/2026/11/20/maha-institute-tax-filings-rfk-jr-health-agenda-spending/ By Isabella CuetoNov. 20, 2026 Chronic Disease Reporter Medicare pilot will test ‘food is medicine’ and other lifestyle programs to counter chronic diseases Kennedy says 15 groups will get a chance to prove preventive programs are worth coverage https://www.statnews.com/2026/11/20/kennedy-food-is-medicine-maha-elevate-pilot/ By Isabella CuetoNov. 20, 2026 Chronic Disease Reporter

When should medical school start? Keep those letters coming!

https://www.statnews.com/2026/11/21/stat-letters-to-editor-medical-school-pediatric-emergency-care/ By Torie BoschNov. 21, 2026 Editor, First Opinion

Patients have little say in how brain implant trials are done. Ian Burkhart wants to change that New recommendations from a patient coalition urge device developers to do better

https://www.statnews.com/2026/11/20/ian-burkhart-how-brain-implant-trials-can-serve-patients-better/ By O. Rose BroderickNov. 20, 2026 Disability in Health Care Reporting Fellow

ICE detention of Princeton scientist rattles academia Case of Chinese graduate student seems to crystallize fears among non-U.S. researchers

https://www.statnews.com/2026/11/20/princeton-researcher-eva-yi-xie-ice-detention-rattles-interational-scholars/ By Anil OzaNov. 20, 2026 General Assignment Reporter

Peptide market poised to explode with new Hims and Noom launches Despite lack of safety data, an HHS decision allows experimental compounds to go mainstream

https://www.statnews.com/2026/11/19/hims-noom-enter-peptide-market-mainstream-products-health-risks/ By Sarah Todd and Katie PalmerNov. 19, 2026

FDA rejects Capricor Therapeutics’ Duchenne therapy, a decision that was a long time coming A public pressure campaign couldn’t alter the hard reality: The drug didn’t work

https://www.statnews.com/2026/11/20/fda-rejects-capricor-duchenne-therapy/ By Adam FeuersteinNov. 20, 2026 Adam Feuerstein, a senior writer and biotech columnist, is the author of Adam’s Biotech Scorecard, a subscriber-only newsletter about the crossroads of drug development, business, Wall Street, and biotechnology.

How Kennedy and MAHA could help stop measles RFK Jr. could reach the vaccine-hesitant during the runaway outbreak

https://www.statnews.com/2026/11/21/rfk-jr-maha-measles-outbreak-elimination-status-promote-mmr-vaccine/ By Brinda AdhikariNov. 21, 2026 Adhikari is a journalist and co-host of the “Why Should I Trust You?” podcast.